Mylan N.V.

Healthcare | Drugs - Generic | USA
Mylan stock spirals after earnings miss and weak guidance

...

Mylan reported fourth-quarter earnings of $51.2 million, or 10 cents a share. After taking out restructuring charges and other costs, the company claimed adjusted earnings of $1.30 a share, down from $1.43 a share in the fourth quarter of 2017. Analysts on average expected Mylan to report adjusted earnings of $1.35 a share, according to FactSet.

Revenue was $3.08 billion, down from $3.24 billion a year ago, but higher than the FactSet consensus of $3.06 billion. Mylan said sales in North America, which fell 18% to $874 million, were hurt by “restructuring and remediation activities” at its Morgantown manufacturing plant that were put into effect after the company received a warning letter in November from the Food and Drug Administration detailing manufacturing violations.

...

https://www.marketwatch.com/story/mylan-...2019-02-27

Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss

Mylan N.V. MYL reported adjusted earnings of 82 cents per share in the first quarter of 2019, which beat the Zacks Consensus Estimate of 79 cents but declined from 96 cents in the year-ago quarter.

However, first-quarter revenues of $2.50 billion missed the Zacks Consensus Estimate of $2.69 billion and declined 7% from the prior-year quarter.

...

https://finance.yahoo.com/news/mylans-my...05098.html